1. Home
  2. SEPN vs PRAA Comparison

SEPN vs PRAA Comparison

Compare SEPN & PRAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SEPN
  • PRAA
  • Stock Information
  • Founded
  • SEPN 2022
  • PRAA 1996
  • Country
  • SEPN United States
  • PRAA United States
  • Employees
  • SEPN N/A
  • PRAA N/A
  • Industry
  • SEPN
  • PRAA Finance: Consumer Services
  • Sector
  • SEPN
  • PRAA Finance
  • Exchange
  • SEPN NYSE
  • PRAA Nasdaq
  • Market Cap
  • SEPN 1.0B
  • PRAA 852.6M
  • IPO Year
  • SEPN 2024
  • PRAA N/A
  • Fundamental
  • Price
  • SEPN $22.53
  • PRAA $23.19
  • Analyst Decision
  • SEPN
  • PRAA Strong Buy
  • Analyst Count
  • SEPN 0
  • PRAA 2
  • Target Price
  • SEPN N/A
  • PRAA $32.00
  • AVG Volume (30 Days)
  • SEPN 399.2K
  • PRAA 327.9K
  • Earning Date
  • SEPN 11-26-2024
  • PRAA 11-04-2024
  • Dividend Yield
  • SEPN N/A
  • PRAA N/A
  • EPS Growth
  • SEPN N/A
  • PRAA N/A
  • EPS
  • SEPN N/A
  • PRAA 1.10
  • Revenue
  • SEPN $838,000.00
  • PRAA $1,042,710,000.00
  • Revenue This Year
  • SEPN N/A
  • PRAA $39.43
  • Revenue Next Year
  • SEPN N/A
  • PRAA $6.61
  • P/E Ratio
  • SEPN N/A
  • PRAA $21.03
  • Revenue Growth
  • SEPN N/A
  • PRAA 29.69
  • 52 Week Low
  • SEPN $18.62
  • PRAA $17.12
  • 52 Week High
  • SEPN $26.34
  • PRAA $31.43
  • Technical
  • Relative Strength Index (RSI)
  • SEPN N/A
  • PRAA 58.82
  • Support Level
  • SEPN N/A
  • PRAA $22.79
  • Resistance Level
  • SEPN N/A
  • PRAA $23.93
  • Average True Range (ATR)
  • SEPN 0.00
  • PRAA 0.98
  • MACD
  • SEPN 0.00
  • PRAA 0.22
  • Stochastic Oscillator
  • SEPN 0.00
  • PRAA 66.42

About SEPN SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.

About PRAA PRA Group Inc.

PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.

Share on Social Networks: